New data demonstrating the safety and efficacy of Enbrel (etanercept) in the treatment of rheumatoid arthritis (RA) patients over the long-term were presented today at the EULAR (European League Against Rheumatism) congress (1). Over 2,000 patients receiving this biologic treatment for up to nine years, saw improvements in disability whilst safety was also sustained over the long-term.
As medical, economic, and policy trends converge to alter the way dialysis care is organized and financed, protecting the unique relationship between dialysis patients and the kidney specialists who direct their care is a top priority, according to a special feature in the July Journal of the American Society of Nephrology.
Sophia Antipolis, France: The European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) have released new Guidelines on the management of Arterial Hypertension, which can be found in the European Heart Journal, the official journal of the ESC and Europe?s leading cardiology journal.
Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced the presentation of additional data that showed that the safety profile of Enbrel? (etanercept) was maintained with long-term use in patients with moderate-to-severe juvenile rheumatoid arthritis (JRA) who completed up to eight years of therapy.
The G8 leaders promised an increase in investment in programs to fight AIDS, tuberculosis, and malaria, but the $60 billion total will still be only one-third of what the UN says is needed over the next five years. Together, these diseases kill about 16,000 people each day.
New data demonstrate that pramipexole (Mirapexin?/Sifrol?) is also efficacious and well-tolerated in Restless Legs Syndrome (RLS) patients with daytime RLS symptoms. The data was presented this week at the Movement Disorder Society?s (MDS) 11th International Congress of Parkinson?s Disease and Movement Disorders in Istanbul, Turkey.
GlaxoSmithKline plc announced results from an international, pivotal Phase III study of its investigational non-peptide oral platelet growth factor, Revolade? (eltrombopag). Data from this study showed that eltrombopag at 50-75mg once daily resulted in a statistically significant increase in platelet counts and also reduced bleeding in adult patients with chronic idiopathic thrombocytopenia purpura (ITP).
US President Bush disappointed in House Vote on Embryonic Stem Cell Bill. The following is a statement by US President Bush:
Anew way to provide clear images of cancerous tumors in the kidney during surgery promises to help physicians preserve as much kidney function as possible while still removing all the malignant tissue ? a significant advance as doctors discover that saving as much healthy kidney tissue as possible is crucial for the future health of cancer patients.
News that scientists have derived cells that behave like stem cells from the skin of a mouse is a major scientific breakthrough that underscores the need to continue human embryonic stem cell research, The Foundation for Taxpayer and Consumer Rights (FTCR) said.